非酒精性脂肪性肝病的治疗进展

冯巩; 牛春燕

doi:10.3969/j.issn.1001-5256.2017.12.041

非酒精性脂肪性肝病的治疗进展

DOI: 10.3969/j.issn.1001-5256.2017.12.041

冯巩,
牛春燕

1. 西安医学院
2. 西安医学院第一附属医院

基金项目:

陕西省普通高等学校优势学科建设项目(陕教位[2014]3号文件)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 1946
- HTML全文浏览量: 12
- PDF下载量: 479
- 被引次数: 0
出版历程
- 收稿日期: 2017-09-18
- 出版日期: 2017-12-20

Advances in the treatment of nonalcoholic fatty liver disease

Xi'an Medical University

Research funding:

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)已成为世界第一大肝病,患病率在持续上升,且作为代谢综合征的组分成为多种严重心脑血管疾病的危险因素。因NAFLD发病机制复杂、共同或相互作用,迄今仍缺乏公认、有效的治疗方法。近年来,越来越多的研究揭示了NAFLD的更多发病机制及相应的治疗前景。介绍了NAFLD的治疗进展,包括生活方式干预、药物治疗、中西医结合模式治疗以及减肥手术,其中药物治疗方面,包括临床常用药物以及最新的处于临床第二、三期试验中的药物及其作用评估。
- 非酒精性脂肪性肝病 /
- 治疗 /
- 综述
Abstract: Nonalcoholic fatty liver disease ( NAFLD) has become a major liver disease in the world and its prevalence rate continues to increase. As a component of metabolic syndrome, it has become a risk factor for many serious cerebrovascular and cardiovascular diseases.Due to the complex pathogenesis of NAFLD or the combined/mutual effect of pathogenic factors, there are still no widely accepted effective therapies. In recent years, more and more studies have revealed new pathogeneses of NAFLD and the prospects of corresponding treatment.This article introduces the recent advances in the treatment of NAFLD, including lifestyle intervention, drug therapy, integrated traditional Chinese and Western medicine therapy, and bariatric surgery. In the aspect of drug therapy, this article introduces the drugs commonly used in clinical practice and new drugs in phase II and III clinical trials and their therapeutic effects.
- nonalcoholic fatty liver disease /
- therapy /
- review

HTML全文

参考文献(55)

[1]HARDY T, OAKLEY F, ANSTEE QM, et al.Nonalcoholic fatty liver disease:pathogenesis and disease spectrum[J].Annu Rev Pathol, 2016, 11 (1) :451-496.

[2]DOWMAN JK, TOMLINSON JW, NEWSOME PN.Pathogenesis o non-alcoholic fatty liver disease[J].QJM, 2010, 103 (2) :69-70.

[3] YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J].Hepatology, 2016, 64 (1) :73-84.

[4]WATANABE S, HASHIMOTO E, IKEJIMA K, et al.Evidencebased clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J].J Gastroenterol, 2015, 50 (4) :364-377.

[5]WONG VW, CHAN WK, CHITTURI S, et al.The Asia-Pacific Working Party on nonalcoholic fatty liver disease guidelines 2017Part 1:definition, risk factors and assessment[J].J Gastroenterol Hepatol, 2017.[Epub ahead of print]

[6]BOUZIANAS DG, BOUZIANA SD, HATZITOLIOS AI.Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids[J].Nutr Rev, 2013, 71 (11) :753-771.

[7]XIN SL, XU KS.A new understanding of the pathogenesis of nonalcoholic fatty liver disease[J].J Clin Hepatol, 2017, 33 (8) :1581-1583. (in Chinese) 辛晟梁, 徐可树.非酒精性脂肪性肝病发病机制新认识[J].临床肝胆病杂志, 2017, 33 (8) :1581-1583.

[8]ZELBER-SAGI S, SALOMONE F, MLYNARSKY L.The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease:evidence and plausible mechanisms[J].Liver Int, 2017, 37 (7) :936-949.

[9]European Association for the Study of the Liver (EASL) ;European Association for the Study of Diabetes (EASD) ;European Association for the Study of Obesity (EASO) .EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease[J].J Hepatol, 2016, 64 (6) :1388-1402.

[10]NASKA A, TRICHOPOULOU A.Back to the future:the Mediterranean diet paradigm[J].Nutr Metab Cardiovasc Dis, 2014, 24 (3) :216-219.

[11]RATZIU V, GOODMAN Z, SANYAL A.Current efforts and trends in the treatment of NASH[J].J Hepatol, 2015, 62 (1) :s65-s75.

[12]van der HEIJDEN GJ, WANG ZJ, CHU ZD, et al.A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents[J].Obesity, 2010, 18 (2) :384-390.

[13]HALLSWORTH K, FATTAKHOVA G, HOLLINGSWORTH KG, et al.Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss[J].Gut, 2011, 60 (9) :1278-1283.

[14]SANYAL AJ, CHALASANI N, KOWDLEY KV, et al.Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J].NEngl J Med, 2010, 362 (18) :1675-1685.

[15]SOCHA P, HORVATH A, VAJRO P, et al.Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children:a systematic review[J].J Pediatr Gastroenterol Nutr, 2009, 48 (5) :587-596.

[16]RAKOSKI MO, SINGAL AG, ROGERS MA, et al.Meta-analysis:insulin sensitizers for the treatment of non-alcoholic steatohepatitis[J].Aliment Pharmacol Ther, 2010, 32 (10) :1211-1221.

[17]SHYANGDAN D, CLAR C, GHOURI N, et al.Insulin sensitisers in the treatment of non-alcoholic fatty liver disease:a systematic review[J].Health Technol Assess, 2011, 15 (38) :1-110.

[18]BOETTCHER E, CSAKO G, PUCINO F, et al.Meta-analysis:pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis[J].Aliment Pharmacol Ther, 2012, 35 (1) :66-75.

[19]LAVINE JE.Vitamin E treatment of nonalcoholic steatohepatitis in children:a pilot study[J].J Pediatr, 2000, 136 (6) :734-738.

[20]HASEGAWA T, YONEDA M, NAKAMURA K, et al.Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis:a pilot study[J].Aliment Pharmacol Ther, 2001, 15 (10) :1667-1672.

[21]MILLER ER 3rd, PASTOR-BARRIUSO R, DALAL D, et al.Meta-analysis:high-dosage vitamin E supplementation may increase all-cause mortality[J].Ann Intern Med, 2005, 142 (1) :37-46.

[22]BJELAKOVIC G, NIKOLOVA D, GLUUD C.Meta-Regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality:do we have evidence for lack of harm?[J].PLo S One, 2013, 8 (9) :e74558.

[23]SAMY W, HASSANIAN MA.Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin[J].Arab J Gastroenterol, 2011, 12 (2) :80-85.

[24]FOSTER T.Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease[J].Am J Gastroenterol, 2010, 106 (1) :71-77.

[25]YOKOHAMA S, YONEDA M, HANEDA M, et al.Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis[J].Hepatology, 2004, 40 (5) :1222-1225.

[26]GEORGESCU EF, IONESCU R, NICULESCU M, et al.Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis[J].World J Gastroenterol, 2009, 15 (8) :942-954.

[27]LIU H, LIU CC, BAO JF.Research advances inω-3 polyunsaturated fatty acids in treatment of nonalcoholic fatty liver disease[J].J Med Res, 2017, 46 (2) :20-22. (in Chinese) 刘慧, 刘晨晨, 包剑锋.ω-3多不饱和脂肪酸治疗非酒精性脂肪肝的研究进展[J].医学研究杂志, 2017, 46 (2) :20-22.

[28]JUMP DB.Fatty acid regulation of hepatic lipid metabolism[J].Curr Opin Clin Nutr Metab Care, 2011, 14 (2) :115-120.

[29]ALI AH, CAREY EJ, LINDOR KD.Recent advances in the development of farnesoid X receptor agonists[J].Ann Transl Med, 2015, 3 (1) :5.

[30]MCGETTIGAN BM, MCMAHAN RH, LUO Y, et al.Sevelamer improves steatohepatitis, inhibits liver and intestinal farnesoid X receptor (FXR) , and reverses innate immune dysregulation in a mouse model of non-alcoholic fatty liver disease[J].J Biol Chem, 2016, 291 (44) :23058-23067.

[31]KONG B, LUYENDYK JP, TAWFIK O, et al.Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet[J].JPharmacol Exp Ther, 2009, 328 (1) :116-122.

[32]CHEN L, YAO X, YOUNG A, et al.Inhibition of apical sodiumdependent bile acid transporter as a novel treatment for diabetes[J].Am J Physiol Endocrinol Metab, 2012, 302 (1) :e68-e76.

[33]RAO A, KOSTERS A, MELLS JE, et al.Inhibition of ileal bile acid uptake protects against non-alcoholic fatty liver disease in high fat diet-fed mice[J].Sci Transl Med, 2016, 8 (357) :357ra122.

[34]FRIEDMAN S, SANYAL A, GOODMAN Z, et al.Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis:CENTAUR Phase 2b study design[J].Contemp Clin Trials, 2016, 47:356-365.

[35]SANYAL AJ, RATZIU V, HARRISON SH, et al.Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis:results from the year 1 primary analysis of the Phase 2b CENTAUR study[EB/OL] (2016-12) [2017-09].https://www.aasld.org/sites/default/files/LBA%20Full%20Abstracts%20Final%20 (Trimmed) .pdf.

[36]BRENNER C, GALLUZZI L, KEPP O, et al.Decoding cell death signals in liver inflammation[J].J Hepatol, 2013, 59 (3) :583-594.

[37]KARNIK S, CHARLTON MR, LI L, et al.Efficacy of an ASK1 inhibitor to reduce fibrosis and steatosis in a murine model of NASH is associated with normalization of lipids and hepatic gene expression and a reduction in serum biomarkers of inflammation and fibrosis[EB/OL]. (2015-11) [2017-09].http://liverlearning.aasld.org/aasld/2015/thelivermeeting/110603/satyajit.karnik.efficacy.of.an.ask1.inhibitor.to.reduce.fibrosis.and.steatosis.html.

[38]LOOMBA R, MANTRY PS, JAYAKUMAR S, et al.GS-4997, an inhibitor of apoptosis signal-regulating kinase (ASK1) , alone or in combination with simtuzumab for the treatment of nonalcoholic steatohepatitis (NASH) :a randomized, phase 2 trial[EB/OL]. (2016-11) [2017-09].http://natap.org/2016/AASLD/AASLD_68.htm.

[39]ADAR T, BEN YA'ACOV A, LALAZAR G, et al.Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells[J].Clin Exp Immunol, 2012, 167 (2) :252-260.

[40]MIZRAHI M, SHABAT Y, BEN YA'ACOV A, et al.Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin:results of a phase I/II clinical trial in NASH[J].J Inflamm Res, 2012, 5:141-150.

[41]ZHU L, BAKER SS, GILL C, et al.Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients:a connection between endogenous alcohol and NASH[J].Hepatology, 2013, 57 (2) :601-609.

[42]LOOMBA R, SEGURITAN V, LI W, et al.Gut microbiomebased metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease[J].Cell Metab, 2017, 25 (5) :1054-1062.

[43]FINNEY J, MOON HJ, RONNEBAUM T, et al.Human copperdependent amine oxidases[J].Arch Biochem Biophys, 2014, 546 (2) :19-32.

[44]JAROLIMEK W, BUSON A, CAO L, et al.Inhibition of lysyl oxidase like 2 reduces collagenaccumulation and collagen cross-links in CCl4-induced liver fibrosis[EB/OL]. (2016-02) [2017-09].http://www.pharmaxis.com.au/assets/Documents/pdf/02016/2016-02-11-Abstract-Keystone-2016.pdf

[45]PENG H, HE Y, ZHENG G, et al.Meta-analysis of traditional herbal medicine in the treatment of nonalcoholic fatty liver disease[J].Cell Mol Biol (Noisy-le-grand) , 2016, 62 (4) :88-95.

[46]LIU ZL, XIE LZ, ZHU J, et al.Herbal medicines for fatty liver dis eases[J].Cochrane Database Syst Rev, 2013, 8 (8) :CD009059.

[47]NIU XY, ZHAO WX.Review of traditional Chinese medicine treatment on nonalcoholic fatty liver disease[J].Tradit Chin Med Res, 2016, 29 (1) :75-78. (in Chinese) 牛逍遥, 赵文霞.非酒精性脂肪性肝病中医研究进展[J].中医研究, 2016, 29 (1) :75-78.

[48]LI HQ, SU SH, SONG J.Review of Chinese and western medicine treatment on nonalcoholic fatty liver disease[J].Clin Focus (Med J) , 2016, 31 (9) :1042-1044. (in Chinese) 李慧卿, 苏少慧, 宋娟.非酒精性脂肪肝中西医治疗新进展[J].临床荟萃, 2016, 31 (9) :1042-1044.

[49]LIU C, LIAO JZ, LI PY.Traditional Chinese herbal extracts inducing autophagy as a novel approach in therapy of nonalcoholic fatty liver disease[J].World J Gastroenterol, 2017, 23 (11) :1964-1973.

[50]RAMOS-LEVI AM, RUBIO MA.Comment on rubino et al.Metabolic surgery in the treatment algorithm for type 2 diabetes:a Joint statement by international diabetes organizations.Diabetes Care2016;39:861-877[J].Diabetes Care, 2017, 40 (7) :e90-e91.

[51]KASAMA K, MUI W, WEI JL, et al.IFSO-APC consensus statements 2011[J].Obes Surg, 2012, 22 (5) :677-684.

[52]LASSAILLY G, CAIAZZO R, BUOB D, et al.Bariatric surgery reduces features of non-alcoholic steatohepatitis in morbidly obese patients[J].Gastroenterology, 2015, 149 (2) :379-388.

[53]AGUILAROLIVOS NE, ALMEDAVALDES P, AGUILARSALI-NAS CA, et al.The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome[J].Metabolism, 2016, 65 (8) :1196-1207.

[54]CLANTON J, SUBICHIN M.The effects of metabolic surgery on fatty liver disease and nonalcoholic steatohepatitis[J].Surg Clin North Am, 2016, 96 (4) :703-715.

[55]HAFEEZ S, AHMED MH.Bariatric surgery as potential treatment for nonalcoholic fatty liver disease:a future treatment by choice or by chance?[J].J Obes, 2013, 2013 (7) :839275.

施引文献

资源附件(0)

访问统计